Top Markets
#1 Akedo Akedo +82.13%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.35%
#4 Cross Cross +45.57%
#5 Black Phoenix Black Phoenix +34.20%
#6 Velvet Velvet +32.22%
#7 Cap Cap +21.97%
#8 OVERTAKE OVERTAKE +20.36%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.80%
#10 QANplatform QANplatform +14.83%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
VivoSim Labs, Inc. VivoSim Labs, Inc.

VivoSim Labs, Inc.

VIVS
Classifica tra le azioni #38727
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company,... VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Prezzo delle azioni
$0.327
Capitalizzazione di mercato
$839.94K
Variazione (1 giorno)
-0.34%
Variazione (1 anno)
-81.83%
Paese
US
Scambia VivoSim Labs, Inc. (VIVS)

Categoria

Healthcare
Utile per VivoSim Labs, Inc. (VIVS)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di VivoSim Labs, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di VivoSim Labs, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE